Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: The North American in Tandem1 study

Diabetes Care

Volumn 41, Issue 9, 2018, Pages 1970-1980

  Buse, John B ^a   Garg, Satish K ^b   Rosenstock, Julio ^c   Bailey, Timothy S ^d   Banks, Phillip ^e   Bode, Bruce W ^f   Danne, Thomas ^g   Kushner, Jake A ^h   Lane, Wendy S ⁱ   Lapuerta, Pablo ^e   McGuire, Darren K ^j   Peters, Anne L ^k   Reed, John ^l   Sawhney, Sangeeta ^e   Strumph, Paul ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c Dallas Diabetes and Endocrine Center at Medical City   (United States)

^d AMCR Institute   (United States)

^e LEXICON PHARMACEUTICALS INC   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h TEXAS CHILDREN S HOSPITAL   (United States)

ⁱ Mountain Diabetes and Endocrine Center   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^l Endocrine Research Solutions Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; PLACEBO; SOTAGLIFLOZIN; (2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(METHYLTHIO)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; GLYCOSIDE; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; BODY WEIGHT; CLINICAL OUTCOME; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES TREATMENT SATISFACTION QUESTIONNAIRE; DIABETIC KETOACIDOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYCOSIS; PARALLEL DESIGN; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOXIC HEPATITIS; URINARY TRACT INFECTION; BLOOD; BODY WEIGHT LOSS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; INSULIN INFUSION; NORTH AMERICA; STANDARDS;

ADULT; AGED; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCATED HEMOGLOBIN A; GLYCOSIDES; HUMANS; HYPOGLYCEMIA; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; NORTH AMERICA; WEIGHT LOSS;

EID: 85052656308     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc18-0343     Document Type: Conference Paper

References (40)

1. Bode BW, Garg SK. The emerging role of adjunctive non insulinanti hyper glycemic therapy in the management of type 1 diabetes. Endocr Pract 2016; 22:220-230
2. Miller KM, Foster NC, Beck RW, et al.; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015; 38:971-978
3. McKnight JA, Wild SH, Lamb MJ, et al. Glycaemic control of type 1 diabetes in clinical practice early in the 21st century: an international comparison. Diabet Med 2015; 32:1036-1050
4. Weiss R, Garg SK, Bode BW, et al. Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE In-Home Study. Diabetes Technol Ther 2015; 17:542-547
5. Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther 2017; 19:155-163
6. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014; 371: 313-325
7. Lu CL, Shen HN, Hu SC, Wang JD, Li CY. A population-based study of all-cause mortality and cardiovascular disease in association with prior history of hypoglycemia among patients with type 1 diabetes. Diabetes Care 2016; 39: 1571-1578
8. Purnell JQ, Braffett BH, Zinman B, et al.; DCCT/ EDIC Research Group. Impact of excessive weight gain on cardiovascular outcomes in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/ EDIC) study. Diabetes Care 2017; 40:1756-1762
9. Lyons SK, Hermann JM, Miller KM, et al. Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49, 996 individuals in the Prospective Diabetes Follow-up and T1D Exchange registries. Diabetes Care 2017; 40: e139-e140
10. Petrie JR, Chaturvedi N, Ford I, et al.; REMOVAL Study Group. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017; 5:597-609
11. Garg SK, Moser EG, Bode BW, et al. Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial. Endocr Pract 2013; 19: 19-28
12. Ellis SL, Moser EG, Snell-Bergeon JK, Rodionova AS, Hazenfield RM, Garg SK. Effect of sitagliptin on glucose control in adult patients with type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med 2011; 28: 1176-1181
13. Mathieu C, Zinman B, Hemmingsson JU, et al.; ADJUNCT ONE Investigators. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care 2016; 39:1702-1710
14. Garg SK, Henry RR, Banks P, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017; 377:2337-2348
15. Dandona P, Mathieu C, Phillip M, et al.; DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5:864-876
16. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodiumglucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care 2015; 38:2258-2265
17. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38:1687-1693
18. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care 2016; 39:532-538
19. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014; 124:509-514
20. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018; 20:1755-1761
21. Lapuerta P, Zambrowicz B, Strumph P, Sands A. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res 2015; 12:101-110
22. Zambrowicz B, Ogbaa I, Frazier K, et al. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dosetiming study in healthy subjects. Clin Ther 2013; 35:1162-1173.e8
23. Dobbins RL, Greenway FL, Chen L, et al. Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol 2015; 308:G946-G954
24. Sands AT, Zambrowicz BP, Rosenstock J, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care 2015; 38:1181-1188
25. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92:158-169
26. Meek TH, Dorfman MD, Matsen ME, et al. Evidence that in uncontrolled diabetes, hyper-glucagonemia is required for ketosis but not for increased hepatic glucose production or hyper-glycemia. Diabetes 2015; 64:2376-2387
27. Garg M, Ghanim H, Kuhadiya ND, et al. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes Obes Metab 2017; 19:1306-1311
28. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015; 21:512-517
29. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Bradley C, Ed. Chur, Switzerland, Harwood Academic Publishers, 1994, p. 111-132
30. Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diabetes Care 2005; 28:626-631
31. 1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40:1622-1630
32. 1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European in Tandem2 study. Diabetes Care 2018; 41:1981-1990
33. Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M. The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes. Diabetes Care 2017; 40:171-180
34. Garg SK, Strumph P. Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med 2018; 378:967-968
35. Weissberg-Benchell J, Antisdel-Lomaglio J, Seshadri R. Insulinpumptherapy: ameta-analysis. Diabetes Care 2003; 26:1079-1087
36. Heller S, White D, Lee E, et al. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess 2017; 21:1-278
37. American Diabetes Association. 14. Diabetes care in the hospital: Standards of Medical Care in Diabetesd 2018. Diabetes Care 2018; 41 (Suppl. 1):S144-S151
38. Weinstock RS, Schütz-Fuhrmann I, Connor CG, et al.; T1D Exchange Clinic Network; DPV Initiative. Type 1 diabetes in older adults: comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. Diabetes Res Clin Pract 2016; 122:28-37
39. Marrero DG, Crean J, Zhang B, et al. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes. Diabetes Care 2007; 30:210-216
40. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015; 17:928-935